AI Terminal
Haleon PLC
Director's Dealing • Sep 26, 2025
5111_dirs_2025-09-26_1dca9006-c800-4d17-b76e-6cc77f70ff71.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 0535B
Haleon PLC
26 September 2025
Haleon plc : Director/PDMR Shareholding
26 September 2025 : Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
On 25 September 2025, the Company was notified of the following transactions as detailed below.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | D awn Allen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | C hief Financial Officer - PDMR | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Haleon plc | |||
| b) | LEI | 549300PSB3WWEODCUP19 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of £0.01 each GB00BMX86B70 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares as a result of dividend reinvestment | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| £3.31963 | 1186.71154 | ||||
| d) | Aggregated information | N/A | |||
| - Aggregated volume | |||||
| - Price | |||||
| e) | Date of the transaction | 23 September 2025 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Keith Choy | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President, Asia Pacific - PDMR | ||||
| b) | Initial notification /Amendment | Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Haleon plc | ||||
| b) | LEI | 549300PSB3WWEODCUP19 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each | ||||
| Identification code | GB00BMX86B70 | |||||
| b) | Nature of the transaction | Acquisition of Ordinary Shares as a result of dividend reinvestment | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| £3.31963 | 3749.41677 | |||||
| d) | Aggregated information | N/A | ||||
| - Aggregated volume | ||||||
| - Price | ||||||
| e) | Date of the transaction | 23 September 2025 | ||||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Filippo Lanzi | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President, EMEA and LATAM - PDMR | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Haleon plc | |||
| b) | LEI | 549300PSB3WWEODCUP19 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of £0.01 each GB00BMX86B70 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares as a result of dividend reinvestment | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| £3.31963 | 2356.42498 | ||||
| d) | Aggregated information | N/A | |||
| - Aggregated volume | |||||
| - Price | |||||
| e) | Date of the transaction | 23 September 2025 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||
| a) | Name | Brian McNamara | ||||||||||
| 2 | Reason for the notification | |||||||||||
| a) | Position/status | Chief Executive Officer - PDMR | ||||||||||
| b) | Initial notification /Amendment | Initial Notification | ||||||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||
| a) | Name | Haleon plc | ||||||||||
| b) | LEI | 549300PSB3WWEODCUP19 | ||||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of £0.01 each GB00BMX86B70 |
||||||||||
| b) | Nature of the transaction | Acquisition of Ordinary Shares as a result of dividend reinvestment | ||||||||||
| c) | Price(s) and volume(s) | |||||||||||
| Price(s) | Volume(s) | |||||||||||
| £3.31963 | 5693.56923 | |||||||||||
| d) | Aggregated information | N/A | ||||||||||
| - Aggregated volume | ||||||||||||
| - Price | ||||||||||||
| e) | Date of the transaction | 23 September 2025 | ||||||||||
| f) | Place of the transaction | London Stock Exchange (XLON) | ||||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||
| a) | Description of the financial instrument, type of instrument Identification code |
Haleon plc American Depositary Shares (ADS) US4055521003 |
||||||||||
| b) | Nature of the transaction | Acquisition of ADSs as a result of dividend reinvestment | ||||||||||
| c) | Price(s) and volume(s) | |||||||||||
| Price(s) | Volume(s) | |||||||||||
| $8.99986 | 2026.50806 | |||||||||||
| d) | Aggregated information | N/A | ||||||||||
| - Aggregated volume | ||||||||||||
| - Price | ||||||||||||
| e) | Date of the transaction | 23 September 2025 | ||||||||||
| f) | Place of the transaction | New York Stock Exchange (XNYS) | ||||||||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Edward Petter | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Chief Corporate Affairs Officer - PDMR | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Haleon plc | |||
| b) | LEI | 549300PSB3WWEODCUP19 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of £0.01 each GB00BMX86B70 |
|||
| b) | Nature of the transaction | Acquisition of Ordinary Shares as a result of dividend reinvestment | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| £3.31963 | 576.54018 | ||||
| d) | Aggregated information | N/A | |||
| - Aggregated volume | |||||
| - Price | |||||
| e) | Date of the transaction | 23 September 2025 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Tamara Rogers | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Marketing Officer - PDMR | ||||
| b) | Initial notification /Amendment | Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Haleon plc | ||||
| b) | LEI | 549300PSB3WWEODCUP19 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of £0.01 each GB00BMX86B70 |
||||
| b) | Nature of the transaction | Acquisition of Ordinary Shares as a result of dividend reinvestment | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| £3.31963 | 1906.13339 | |||||
| d) | Aggregated information | N/A | ||||
| - Aggregated volume | ||||||
| - Price | ||||||
| e) | Date of the transaction | 23 September 2025 | ||||
| f) | Place of the transaction | London Stock Exchange (XLON) | ||||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBBGDCXUDDGUL